The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1564
ISSUE1564
January 28, 2019
Revefenacin (Yupelri) for COPD
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Revefenacin (Yupelri) for COPD
January 28, 2019 (Issue: 1564)
The FDA has approved revefenacin (Yupelri – Mylan/Theravance Biopharma), a long-acting antimuscarinic
agent (LAMA) administered once daily by standard
jet nebulizer, for maintenance treatment of chronic
obstructive pulmonary disease (COPD)....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.